SEC Tracker
Get the app

aTYR PHARMA ATYR

aTyr Pharma files prospectus supplement for stock sale

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Up to $79,994,251 in common stock may be sold
  2. Filed under shelf registration (lets the company sell securities later) statement on Form S-3
  3. Prospectus supplement filed with SEC on Nov 6, 2026
  4. Sales agreement with Jefferies LLC dated April 22, 2022

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when aTYR PHARMA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Arvinas ARVN public float $469M, Jun 30, 2025
  2. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  3. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  4. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  5. Myriad Genetics MYGN public float $494M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.